Business
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June - DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biot
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mm54aqS3.8GpFHiIkOCKDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mm54aqS3.8GpFHiIkOCKDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - ","length":96,"tagName":"p"},{"type":"text","content":"- The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - ","length":151,"tagName":"p"},{"type":"text","content":"- Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June -","length":149,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research providing evidence of self-repair of the acellular tissue engineered vessel (ATEV) after cannulation for dialysis access at the Vascular Access Society of the Americas (VASA) 2026 Vascular Access for Dialysis Symposium in Salt Lake City, Utah. The presentation, titled “Self-repair of Acellular Tissue Engineered Vessels (ATEV) after Cannulation for Dialysis Access,” was delivered by Maisha Clancy, MA, Process Development Engineer at Humacyte. Research demonstrated that despite repeated cannulations for dialysis access, the ATEV was observed to maintain long-term structural integrity self-repair with smooth muscle cell repopulation in explants up to 5.5 years post-implantation.","length":947,"tagName":"p"},{"type":"text","content":"Arteriovenous (AV) fistulas remain the standard of care for vascular acce...